Keryx Biopharm Inc (KERX) 4.72 $KERX Downgrade Alert for

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Keryx Biopharm Inc (KERX) 4.72 $KERX

Downgrade Alert for Keryx Biopharmaceuticals (KERX)
Comtex SmarTrend(R) - 2 hrs 1 min ago
Keryx Biopharmaceuticals (NASDAQ:KERX) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $4.72 on volume of 14.0 million shares, above average daily volume of 2.1 million. Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.
KERX: 4.72 (-2.64)

INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Keryx Biopharmaceuticals Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Mon Aug 01, 7:53PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company" (Nasdaq: KERX) concerning possible violations of federal securities laws.
KERX: 4.72 (-2.64)

Glancy Prongay & Murray Commences Investigation on Behalf of Keryx Pharmaceuticals, Inc. Investors
BusinessWire - Mon Aug 01, 5:41PM CDT
Glancy Prongay & Murray LLP ("GPM" announces an investigation on behalf of investors of Keryx Pharmaceuticals, Inc. ("Keryx" or the "Company" (NASDAQ: KERX) concerning the Company and its officers' possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Falls 30.57% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 01, 3:47PM CDT
Keryx Biopharmaceuticals (NASDAQ:KERX) traded in a range yesterday that spanned from a low of $4.81 to a high of $5.35. Yesterday, the shares fell 30.6%, which took the trading range below the 3-day low of $7.25 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
KERX: 4.72 (-2.64)

Keryx (KERX) Q2 Loss Wider than Expected, Withdraws View
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:22AM CDT
Keryx (KERX) reported a loss of 42 cents in second-quarter of 2016, above the Zacks Consensus Estimate of 29 cents.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia(R) (ferric citrate) and Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 01, 6:30AM CDT
- Supply interruption does not affect the safety profile of currently available Auryxia -
KERX: 4.72 (-2.64)

Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.15 (-0.27), IRWD: 13.94 (-0.19), KERX: 4.72 (-2.64), EXEL: 9.27 (+0.09)

Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2016 Financial Results on Monday, August 1, 2016
GlobeNewswire - Fri Jul 29, 7:30AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that it will host a conference call and webcast on Monday, August 1, 2016 at 8:30 a.m. ET to discuss its second quarter 2016 financial results and provide a company update.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Up 64.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Jul 27, 12:44PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 5 months, Keryx Biopharmaceuticals has returned 64.77% as of today's recent price of $7.39.
KERX: 4.72 (-2.64)

Keryx Biopharma, Waddell & Reed Financial, Benchmark Electronics, Ryerson Holding and Wex highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:30AM CDT
Keryx Biopharma, Waddell & Reed Financial, Benchmark Electronics, Ryerson Holding and Wex highlighted as Zacks Bull and Bear of the Day
RYI: 14.67 (+0.23), BHE: 23.64 (+0.20), WEX: 91.96 (-1.72), WDR: 18.37 (+0.11), KERX: 4.72 (-2.64)

Bull of the Day: Keryx Biopharma (KERX)
Brian Bolan - ZACKS - Tue Jul 26, 7:12AM CDT
Bull of the Day: Keryx Biopharma (KERX)
KERX: 4.72 (-2.64)

Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.22 (-0.04), SCYX: 2.00 (-0.02), CFRX: 2.40 (unch), MNTA: 11.34 (+0.08), KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Has Returned 37.7% Since SmarTrend Recommendation (KERX)
Comtex SmarTrend(R) - Fri Jun 17, 12:55PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 4 months, Keryx Biopharmaceuticals has returned 37.73% as of today's recent price of $6.18.
KERX: 4.72 (-2.64)

Shares of KERX Up 34.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:31AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 34.89% as of today's recent price of $6.05.
KERX: 4.72 (-2.64)

Shares of KERX Up 53.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:04PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 53.85% as of today's recent price of $6.90.
KERX: 4.72 (-2.64)

Keryx Biopharmaceuticals Up 22.4% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed May 18, 1:20PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 3 months, Keryx Biopharmaceuticals has returned 22.41% as of today's recent price of $5.49.
KERX: 4.72 (-2.64)

Uptrend Call Working As Keryx Biopharmaceuticals Stock Rises 27.1% (KERX)
Comtex SmarTrend(R) - Tue May 03, 12:56PM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on March 2nd, 2016 at $4.49. In approximately 2 months, Keryx Biopharmaceuticals has returned 27.09% as of today's recent price of $5.70.
KERX: 4.72 (-2.64)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 38

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 76

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 79

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 146

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 49

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 171

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 138

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Artisan Partners Asset Management's Q2 Performance and Highlights

Updated Category News Views 124

Artisan Partners Asset Management Inc. Reports Strong Q2 Performance Artisan Partners Asset Management Inc. (NYSE: APAM) recently showcased its financial success for the quarter ending June 30, 2025. The Company, renowned for its investment strategies, declared a quarterly dividend as part of its results presentation. This reflects Artisan's commitment to providing value...

Continue Reading
LVMH Reports Recent Share Transactions and Market Activity

Updated Category News Views 240

Understanding LVMH's Share Transactions Recently, LVMH Moët Hennessy Louis Vuitton disclosed share transactions conducted between exciting dates. This information was provided to the regulatory body, ensuring transparency for investors and industry stakeholders alike. As one of the leading companies in the luxury goods sector, LVMH’s transactions are always...

Continue Reading
Dynavax Technologies to Share Insights at Healthcare Conference

Updated Category News Views 160

Dynavax's Upcoming Participation in Healthcare Conference Dynavax Technologies Corporation (Nasdaq: DVAX), a prominent player in the biopharmaceutical landscape, is set to take part in a pivotal fireside chat at the 8th Annual Evercore Healthcare Conference. This insightful event will take place on an upcoming Tuesday at 2:10 p.m. ET. Investors and healthcare stakeholders...

Continue Reading
Growing Demand for 3D Surveillance Cameras by 2030

Updated Category News Views 301

The Growing Market for 3D Surveillance Cameras The global 3D surveillance camera market is on the brink of substantial growth, with forecasts indicating it could reach an impressive $7.92 billion by 2030. This surge is primarily fueled by increased investments in defense and public safety initiatives around the world. A key factor in this trend is the rising use of 3D...

Continue Reading
LVMH Stock Upgrade by BofA Signals Strong Growth Ahead

Updated Category News Views 317

LVMH Receives Positive Rating Upgrade from Bank of America Recently, Bank of America made headlines by upgrading LVMH shares to a Buy rating, moving it from a previous Neutral stance. This upgrade places the renowned luxury goods giant on its prestigious Europe 1 list of preferred investment ideas. Revised Price Targets Indicate Strong Potential The ratings agency has...

Continue Reading